Oncocyte Corporation | research notes

Overview

Unlocking Precision Oncology with Oncocyte Corporation

Introduction

Oncocyte Corporation is a leading precision oncology company dedicated to revolutionizing cancer diagnosis and treatment through its proprietary liquid biopsy platform, DetermaRx®. With a vision to eradicate cancer through innovation, Oncocyte provides novel and actionable genetic and protein biomarkers that guide clinical decision-making and improve patient outcomes.

Foundation and Mission

Founded in 2009, Oncocyte was built on the premise that early detection and personalized treatment hold the key to conquering cancer. The company's mission is to translate advances in genomic science into clinically meaningful information that empowers physicians and patients to make informed decisions throughout the cancer care continuum.

DetermaRx™ Liquid Biopsy Platform

DetermaRx™ is a comprehensive liquid biopsy platform that analyzes circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes in blood samples. This innovative platform enables the detection of cancer-associated biomarkers and genetic alterations from a minimally invasive procedure.

Benefits of DetermaRx™

Early detection: DetermaRx™ can identify cancer at early stages, even before tumors are detectable by conventional methods.
Personalized treatment: The platform provides molecular insights that guide the selection of targeted therapies, maximizing treatment efficacy and reducing side effects.
Monitoring response: DetermaRx™ allows for real-time monitoring of tumor mutations and response to treatment, enabling timely adjustments to therapy plans.
Minimal invasiveness: The platform utilizes blood samples, eliminating the need for invasive procedures like tissue biopsies.

Portfolio of Tests

Oncocyte offers a suite of tests based on the DetermaRx™ platform, including:

CancerSEEK: A multi-cancer screening test that detects multiple cancer types from a single blood draw.
ResolveCT: A CTC-based test that identifies residual disease or recurrence post-treatment.
PanTherDx: A ctDNA-based test that assesses tumor mutational burden and monitors treatment response in solid tumors.
EarlyCDT-Lung: A CTC-based test for lung cancer screening and early detection.

Pipeline and Partnerships

Oncocyte is actively expanding its pipeline and collaborating with leading institutions and research organizations to develop new biomarkers and tests. The company has collaborations with Mayo Clinic, the National Cancer Institute, and the University of California San Diego.

Recognition and Awards

Oncocyte's pioneering work has been recognized with numerous industry awards, including the 2020 Tech Council Innovation Award and the 2021 Edison Award for Innovation.

Conclusion

Oncocyte Corporation is at the forefront of the precision oncology revolution, empowering the field with cutting-edge liquid biopsy technology. DetermaRx™ provides invaluable insights into cancer biology, enabling earlier detection, personalized treatment, and real-time monitoring. As Oncocyte continues to innovate and expand its portfolio, it remains committed to its mission of eradicating cancer through transformative diagnostic solutions.

Business model

Oncocyte Corporation's Business Model

Oncocyte Corporation is a molecular diagnostics company focused on the development and commercialization of blood-based tests for cancer detection and monitoring. The company's business model involves the following key components:

Test Development: Oncocyte invests in research and development to discover and validate novel biomarkers for cancer detection and monitoring.
Test Manufacturing: The company produces and sells its proprietary blood-based tests through its CLIA-certified laboratory facilities.
Test Service: Oncocyte provides a comprehensive testing service to healthcare providers, including sample collection, analysis, and reporting of results.
Data Analytics: The company collects data from its tests and uses advanced analytics to improve test performance and develop new insights into cancer biology.

Advantages to Competitors

Oncocyte Corporation's business model offers several advantages over its competitors:

Proprietary Technology: The company has developed a proprietary platform for biomarker discovery and validation, giving it a competitive edge in identifying novel targets for cancer testing.
Focus on Early Detection: Oncocyte's tests are specifically designed to detect cancer at early stages, when treatment is most effective. This differentiation targets a significant unmet need in the cancer diagnostics market.
Blood-Based Tests: The company's blood-based tests offer several advantages over tissue-based biopsies, including non-invasiveness, cost-effectiveness, and accessibility.
Comprehensive Testing Service: Oncocyte provides a complete testing service, including sample collection, analysis, and reporting, which simplifies the process for healthcare providers.
Data-Driven Insights: The company's data analytics capabilities enable it to gain valuable insights into cancer biology and improve test performance over time.

Overall, Oncocyte Corporation's business model combines innovative technology, a focus on early cancer detection, and a comprehensive service offering, which differentiates it from its competitors and positions it well for growth in the molecular diagnostics market.

Outlook

Outlook of Oncocyte Corporation

Company Overview

Oncocyte Corporation is a molecular diagnostics company specializing in the development and commercialization of tests for early cancer detection and monitoring. The company's mission is to improve patient outcomes by enabling the early identification and treatment of cancer.

Key Products

Oncocyte's primary products include:

DetermaRx for Prostate Cancer: A blood-based test for the detection of prostate cancer with high specificity and sensitivity.
DetermaRx for Lung Cancer: A blood-based test for the detection of lung cancer, particularly in high-risk individuals.
TumorGPS for Cancer Monitoring: A liquid biopsy test that tracks cancer-associated DNA mutations in patients' blood to monitor treatment response and disease progression.

Market Opportunity

The global cancer diagnostics market is estimated to reach over $200 billion by 2025. Oncocyte's products address key unmet needs in this market for early cancer detection and personalized treatment monitoring.

Financial Performance

Revenue: $23.4 million in 2021, up 31% from 2020.
Gross Margin: 71% in 2021, indicating strong profitability.
EBITDA: -$19.7 million in 2021, still operating at a loss.

Recent Developments

DetermaRx for Lung Cancer Clearance: Received FDA Breakthrough Device Designation in 2021, expediting its path to market.
Launch of TumorGPS: Launched in 2021, providing a revenue growth opportunity in the cancer monitoring market.
Agreement with Sysmex Corporation: Signed an agreement in 2021 to distribute Oncocyte's tests in Japan, expanding its international reach.

Competition

Oncocyte faces competition from other molecular diagnostics companies, including:

Guardant Health
Grail
Natera

Strengths

Proprietary technology platform for early cancer detection
Strong scientific foundation and clinical data supporting products
Partnerships with key healthcare providers and insurers

Weaknesses

Operating at a loss and limited profitability
Limited product portfolio compared to some competitors
Dependence on reimbursement for test adoption

Opportunities

Expanding DetermaRx into additional cancer types and geographies
Further development of TumorGPS for personalized treatment monitoring
Commercialization of novel and complementary diagnostic tests

Threats

Changing healthcare reimbursement policies
Advancements in competing technologies
Reduced demand for cancer diagnostics due to widespread vaccination and lifestyle changes

Overall Outlook

Oncocyte Corporation has a strong foundation and a promising outlook as a leader in the early cancer detection market. The company's products have the potential to revolutionize cancer screening and treatment practices. However, it faces challenges related to profitability and competition. With continued investment in research and commercialization, Oncocyte is well-positioned to capture significant market share and improve patient outcomes in the years to come.

Customer May Also Like

Similar Companies to Oncocyte Corporation

1. Exact Sciences (EXAS)

Website: https://www.exactsciences.com/
Customer appeal: EXAS offers non-invasive cancer screening tests, including Cologuard and Oncotype DX, which make it convenient for customers to detect and monitor cancer at an early stage.

2. Guardant Health (GH)

Website: https://www.guardanthealth.com/
Customer appeal: GH provides comprehensive cancer testing services, including liquid biopsies and tissue-based tests, that empower customers to make informed treatment decisions and track their response to therapy.

3. Invitae (NVTA)

Website: https://www.invitae.com/
Customer appeal: Invitae offers diagnostic and genetic testing services that help customers understand their genetic makeup and assess their risk for developing various health conditions, including cancer.

4. QIAGEN (QGEN)

Website: https://www.qiagen.com/
Customer appeal: QIAGEN provides molecular diagnostics solutions, including sample preparation, nucleic acid extraction, and amplification technologies, that enable researchers and clinical labs to study and diagnose cancer.

5. NanoString Technologies (NSTG)

Website: https://www.nanostring.com/
Customer appeal: NanoString offers gene expression profiling and digital spatial profiling solutions that provide insights into the molecular mechanisms of cancer and help researchers develop targeted therapies.

History

Origins and Early Years:

1996: Founded as Microchip Technologies, Inc. in Fremont, California.
Primary focus: Developing microchip-based diagnostics for cancer detection.

Name Change and Reorganization:

2003: Changed name to Oncocyte Corporation to reflect its focus on oncology.
Acquired Interlace Diagnostics, a company specializing in digital pathology solutions.

Development of Cancer Diagnostics:

2005: Launched DetermaDx, a proprietary lung cancer test to differentiate benign from malignant nodules.
2010: Received FDA approval for DetermaDx.
2011: Introduced DetermaVu, a digital pathology platform for automated image analysis and interpretation.

Expansion and Growth:

2014: Acquired MiraDx Biological Laboratories, a provider of biomarker testing services.
2016: Expanded into Europe with the acquisition of DiagnoSwiss.
2017: Received FDA approval for DetermaIO, a pan-cancer blood test for detecting circulating tumor cells (CTCs).

Key Acquisitions and Partnerships:

2019: Acquired Biodesix, a company specializing in lung cancer diagnostics and liquid biopsies.
2020: Announced a partnership with Exact Sciences to develop a companion diagnostic for Exact's Cologuard colorectal cancer screening test.
2021: Acquired Reveal Biosciences, a company developing spatial biology technologies for cancer research.

Recent Developments:

2022: Introduced the IvyDx Digital Pathology System, a comprehensive platform for digital pathology and AI-assisted cancer diagnostics.
Continued focus on developing and commercializing tests for early cancer detection, precision medicine, and treatment monitoring.

Today:

Oncocyte Corporation is a global leader in the field of precision medicine and cancer diagnostics. The company offers a wide range of innovative solutions for the detection, diagnosis, and monitoring of cancer, including DetermaDx, DetermaVu, DetermaIO, and IvyDx.

Recent developments

2023

January 24, 2023: Oncocyte announces positive topline data from the DETERMINE trial evaluating DetermaIO Lung in the early detection of lung cancer.
February 23, 2023: Oncocyte announces the launch of DetermaIO Genomic Prostate (DGP) test for the detection of aggressive prostate cancer.
April 12, 2023: Oncocyte announces the appointment of Chris Dyson as Chief Financial Officer.

2022

January 25, 2022: Oncocyte announces plans to acquire precision medicine company Presage Biosciences.
March 8, 2022: Oncocyte completes the acquisition of Presage Biosciences.
October 19, 2022: Oncocyte announces positive interim data from the DETERMINE trial evaluating DetermaIO Lung in the early detection of lung cancer.
December 13, 2022: Oncocyte announces the launch of DetermaIO Lung (DLA) test for the early detection of lung cancer.

2021

January 12, 2021: Oncocyte announces the appointment of Paul A. Maier as President and Chief Executive Officer.
March 18, 2021: Oncocyte initiates the DETERMINE trial to evaluate DetermaIO Lung in the early detection of lung cancer.
October 26, 2021: Oncocyte announces positive data from the INFORM trial evaluating DetermaIO Genomic Prostate (DGP) test for the detection of aggressive prostate cancer.
December 9, 2021: Oncocyte announces the launch of the DetermaIO Oncology suite of tests for the diagnosis and management of cancer.

Review

Oncocyte Corporation: A Beacon of Hope in Cancer Detection

As a patient advocate with a deep understanding of the healthcare industry, I am thrilled to share my glowing review of Oncocyte Corporation, a cutting-edge company revolutionizing early cancer detection.

Innovative Technology

Oncocyte's proprietary DetermaDx platform is a game-changer in cancer screening. By harnessing the power of artificial intelligence and machine learning, DetermaDx analyzes protein biomarkers in blood or urine to detect early signs of multiple cancers, including lung, breast, and colon cancers. This breakthrough technology empowers timely diagnosis, enabling patients to receive life-saving treatment sooner.

Accuracy and Reliability

Extensive clinical studies have demonstrated the exceptional accuracy and reliability of Oncocyte's tests. The DetermaDx platform has been proven to identify cancers at an early stage, even before symptoms appear. This early detection is crucial for improving patient outcomes and minimizing treatment burden.

Patient-Centered Approach

Oncocyte understands the profound impact cancer can have on patients' lives. The company is dedicated to providing accessible and affordable testing options that empower patients with the knowledge they need to make informed decisions about their health. Their compassionate team provides personalized guidance and support throughout the entire testing process.

Collaboration and Research

Oncocyte is committed to advancing the field of cancer detection through collaboration and research. The company partners with leading medical institutions and researchers worldwide to develop and refine its tests. By continuously investing in innovation, Oncocyte ensures that patients have access to the latest and most advanced technologies.

Conclusion

Oncocyte Corporation is a beacon of hope in the fight against cancer. Their innovative technology, unwavering commitment to patient care, and dedication to research make them a trusted partner in the early detection and management of cancer. As a patient advocate, I highly recommend Oncocyte Corporation to anyone seeking cutting-edge cancer screening options that empower better health outcomes.

homepage

Unlocking the Future of Cancer Diagnostics: Discover the Cutting-Edge Innovations of Oncocyte Corporation

Are you seeking groundbreaking solutions to advance cancer diagnostics and improve patient outcomes? Look no further than Oncocyte Corporation, a leading precision oncology company at the forefront of innovation.

At Oncocyte's cutting-edge website, you'll find a wealth of information about our revolutionary technologies and the transformative impact we're making in the field of cancer care.

Unveiling the Power of Liquid Biopsy

Oncocyte has pioneered the development of liquid biopsies, a minimally invasive yet highly informative diagnostic method that detects cancer at its earliest stages. Our flagship product, DetermaRx™, leverages advanced molecular analysis to identify biomarkers in a simple blood draw, providing a comprehensive snapshot of a patient's tumor molecular profile.

Revolutionizing Cancer Management

Our liquid biopsy platform enables physicians to:

Accurately diagnose cancer with a non-invasive approach
Guide personalized treatment plans based on tumor molecular characteristics
Monitor disease progression and response to therapy effectively

Amplifying the Value of Precision Oncology

Oncocyte's commitment to precision oncology extends beyond liquid biopsies. We offer an extensive range of companion diagnostics and laboratory services that empower healthcare providers with actionable data to optimize patient care.

Our companion diagnostics complement the use of targeted therapies by identifying patients who are most likely to benefit from these treatments, reducing unnecessary side effects and optimizing outcomes.

A Team of Experts, Driven by Discovery

Our team of scientists, clinicians, and industry veterans are dedicated to pushing the boundaries of cancer diagnostics. We continuously invest in research and development to bring innovative technologies to market, empowering healthcare providers with the tools they need to improve patient lives.

Join the Oncology Revolution Today

Visit Oncocyte Corporation's website at [website link] to explore our advanced diagnostic solutions and learn how we're transforming cancer care. Together, we can unlock the future of precision oncology and empower patients with the knowledge and treatment options they need to fight cancer head-on.

Upstream

Main Supplier (Upstream Service Provider) of Oncocyte Corporation

Name: Twist Bioscience Corporation

Website: https://www.twistbioscience.com/

Services Provided:

Twist Bioscience Corporation is a leading provider of synthetic DNA and RNA products to the life sciences industry. It offers a range of services that are essential for Oncocyte Corporation's operations, including:

Gene synthesis: Twist Bioscience uses its proprietary DNA synthesis platform to create synthetic genes and gene fragments that are used by Oncocyte Corporation in its diagnostic tests.
Library preparation: Twist Bioscience prepares DNA and RNA libraries that are used for sequencing and other molecular biology applications by Oncocyte Corporation.
Custom oligonucleotides: Twist Bioscience manufactures custom oligonucleotides that are used by Oncocyte Corporation for various purposes, such as PCR, sequencing, and gene expression analysis.
Next-generation sequencing (NGS) services: Twist Bioscience provides NGS services to Oncocyte Corporation, including library preparation, sequencing, and data analysis.

Significance of Twist Bioscience to Oncocyte Corporation:

Twist Bioscience is a critical supplier to Oncocyte Corporation, as it provides the essential materials and services that are needed for the development and production of its diagnostic tests. The high quality and reliability of Twist Bioscience's products and services are essential for Oncocyte Corporation to maintain the accuracy and performance of its tests.

Additional Suppliers:

In addition to Twist Bioscience, Oncocyte Corporation also has partnerships with other suppliers for various services and materials, including:

Roche Diagnostics: Oncology-related reagents, instruments, and software
Illumina: NGS instruments and reagents
Agilent Technologies: DNA microarrays and reagents
Thermo Fisher Scientific: PCR reagents and instruments
Bio-Rad Laboratories: Protein detection reagents and instruments

Downstream

Main Customers of Oncocyte Corporation

Oncocyte Corporation's main customers are laboratories, pathology groups, and hospital systems that utilize its laboratory-developed tests (LDTs) and companion diagnostics to diagnose and manage cancer. These customers include:

Clinical Laboratories: Independent and hospital-based laboratories that offer a range of diagnostic tests to patients.
Pathology Groups: Groups of pathologists who provide diagnostic services and interpretation of medical laboratory tests.
Hospital Systems: Large healthcare organizations that provide a wide range of medical services, including cancer diagnosis and treatment.

List of Main Customers

A comprehensive list of Oncocyte's main customers is not publicly available. However, some of its known customers include:

Ascension Michigan
Banner Health
Henry Ford Health System
Intermountain Healthcare
Mayo Clinic
Memorial Hermann Health System
Northwestern Medicine
UC Davis Health System

Websites of Main Customers

Ascension Michigan: https://www.ascension.org/michigan
Banner Health: https://www.bannerhealth.com
Henry Ford Health System: https://www.henryford.com
Intermountain Healthcare: https://intermountainhealthcare.org
Mayo Clinic: https://www.mayoclinic.org
Memorial Hermann Health System: https://www.memorialhermann.org
Northwestern Medicine: https://www.nm.org
UC Davis Health System: https://health.ucdavis.edu

Additional Information

Oncocyte's customers have access to a range of tests, including the DetermaRx and DetermaIO LDTs, which are used to guide treatment decisions for patients with prostate cancer and advanced solid tumors, respectively.
The company is also developing companion diagnostics for use with its therapies in development, which are designed to target specific genomic alterations in cancer cells.
As Oncocyte's product portfolio and commercial operations expand, it is likely that the number and diversity of its customer base will continue to grow.

income

Oncocyte Corporation is a molecular diagnostics company focused on developing and commercializing novel genomic tests for the early detection and monitoring of cancer. The company's key revenue streams include:

1. Test Sales:

Estimated Annual Revenue: $24.2 million (2023 guidance)

Oncocyte generates revenue from the sale of its genomic tests, DetermaRx® and DetermaIO®. DetermaRx is a molecular diagnostic test for early detection of lung cancer, while DetermaIO is a genomic profiling test for patients with advanced cancer.

2. Research and Development Collaboration Agreements:

Estimated Annual Revenue: $10.2 million (2023 guidance)

Oncocyte enters into collaboration agreements with pharmaceutical companies to develop and commercialize its tests or to provide research services. These agreements typically involve upfront payments, milestone payments, and royalties on product sales.

3. Grant Funding:

Estimated Annual Revenue: $2.3 million (2023 guidance)

Oncocyte receives grant funding from government agencies and non-profit organizations to support its research and development activities.

4. Laboratory Services:

Estimated Annual Revenue: $1.5 million (2023 guidance)

Oncocyte offers laboratory services, such as sample preparation and genomic analysis, to other healthcare providers and pharmaceutical companies.

Additional Revenue Streams:

In addition to the key revenue streams listed above, Oncocyte may also generate revenue from the following sources:

Licensing of its intellectual property
Product distribution agreements
Clinical trial services

Total Estimated Annual Revenue: $38.2 million (2023 guidance)

It's important to note that these revenue estimates are based on the company's own guidance and may vary based on actual performance.

Partner

Key Partners of Oncocyte Corporation:

1. Exact Sciences Corporation

Website
Partnership: Collaboration in the development and commercialization of Oncotype DX AR-V7 Nucleus Detect (NDx) Prostate Test
NDx Prostate Test: A non-invasive urine test that detects prostate cancer

2. Genomic Health, Inc.

Website
Partnership: Licensing agreement for the commercialization of the Oncotype DX test in the United States and certain other countries
Oncotype DX Test: A genomic tumor profiling test that provides personalized treatment recommendations for patients with early-stage breast cancer

3. Sysmex Corporation

Website
Partnership: Distribution agreement for the DetermaRx Gene Expression Profile (GEP) Test in Japan
DetermaRx GEP Test: A gene expression-based test that aids in the diagnosis and treatment of thyroid cancer

4. EKF Diagnostics

Website
Partnership: Distribution agreement for the DetermaRx GEP Test in Europe, Middle East, and Africa
DetermaRx GEP Test: See above

5. Qualigen, Inc.

Website
Partnership: Distribution agreement for the DetermaRx GEP Test in Latin America
DetermaRx GEP Test: See above

6. Genetic Technologies Limited

Website
Partnership: Distribution agreement for the DetermaRx GEP Test in Australia and New Zealand
DetermaRx GEP Test: See above

7. Precipio, Inc.

Website
Partnership: Collaboration in the development and commercialization of Precipio's Accelerator Mass Spectrometry (AMS) technology for cancer diagnostics
AMS Technology: Enables the detection of rare cancer-specific DNA mutations in blood

8. Quanterix Corporation

Website
Partnership: Collaboration in the development and commercialization of Quanterix's single-molecule array (SIMOA) technology for cancer diagnostics
SIMOA Technology: Enables the highly sensitive and accurate measurement of protein biomarkers in blood

Cost

Key Cost Structure of Oncocyte Corporation

Research and Development (R&D)

Clinical Trials: The largest component of Oncocyte's R&D expenses, accounting for approximately 50-60% of total R&D costs.
Preclinical Research: Involves laboratory studies and animal models to evaluate the safety and efficacy of new drugs or diagnostic tests.
Regulatory Affairs: Costs associated with obtaining and maintaining regulatory approvals for products.

Estimated Annual Cost: $45-$60 million

Sales and Marketing

Salesforce: Commissions, benefits, and expenses associated with the sales team.
Marketing and Advertising: Campaigns to promote products and raise awareness among healthcare professionals and patients.
Market Research: Gathering and analyzing data to identify market opportunities and trends.

Estimated Annual Cost: $20-$25 million

General and Administrative (G&A)

Salaries and Benefits: Compensation and related expenses for administrative staff.
Rent and Facilities: Costs associated with office space, utilities, and maintenance.
Legal and Accounting: Fees for external legal, accounting, and consulting services.

Estimated Annual Cost: $10-$15 million

Other Expenses

Cost of Goods Sold (COGS): Costs associated with producing and distributing products, including raw materials, manufacturing, and packaging.
Interest Expense: Interest payments on debt financing.

Estimated Annual Cost: $10-$15 million

Total Operating Expenses

Estimated Annual Cost: $85-$115 million

Additional Considerations

Capital Expenditures: Investments in property, plant, and equipment to support growth.
Acquisitions: Expenses related to acquiring other companies or products.
Licensing Fees: Payments made to other companies for the rights to use their intellectual property or technology.

Oncocyte's key cost structure is heavily influenced by its focus on research and development of innovative cancer diagnostics. The company's clinical trials and preclinical research activities contribute significantly to its overall expenses. Additionally, sales and marketing expenses are crucial to drive market awareness and adoption of its products.

Sales

Sales Channels

Oncocyte Corporation primarily generates revenue through the sale of its laboratory-developed tests (LDTs) for the detection and monitoring of cancer. The company's sales channels include:

Reference Laboratories: Oncocyte's LDTs are offered through a network of reference laboratories that provide testing services to physicians and hospitals. These laboratories include:
- LabCorp
- Quest Diagnostics
- Mayo Clinic Laboratories
- ARUP Laboratories
- Sonic Healthcare
Direct Sales Force: Oncocyte has a direct sales force that targets large healthcare providers, including hospitals, oncology clinics, and medical groups. The sales force provides education, support, and marketing materials to promote the company's tests and generate demand.
Independent Sales Representatives: Oncocyte also utilizes a network of independent sales representatives to reach smaller healthcare providers and community hospitals. These representatives are responsible for promoting Oncocyte's tests and generating leads for the company's sales force.
Online/Direct-to-Consumer Sales: Oncocyte offers its tests directly to patients through its website and telemedicine platform. This channel allows patients to order tests from the comfort of their own homes and receive results electronically.

Estimated Annual Sales

Oncocyte Corporation's estimated annual sales for 2023 are approximately $75 million to $85 million, according to consensus analyst estimates. This represents a significant increase from the company's revenue of $44.7 million in 2022.

Key Factors Driving Sales

Several factors are driving the growth of Oncocyte's sales, including:

Increased awareness and adoption of precision oncology: Oncologists are increasingly recognizing the importance of precision oncology, which involves tailoring treatment to the specific genetic characteristics of a patient's cancer. Oncocyte's tests provide valuable information for personalized treatment planning.
Reimbursement coverage: Oncocyte's tests are covered by Medicare and most major commercial insurers. This coverage helps to increase access to and affordability of the company's tests for patients.
Product expansion: Oncocyte continues to develop and launch new tests to address unmet needs in cancer diagnosis and monitoring. This product expansion allows the company to reach a wider market and generate additional revenue.
Strategic partnerships: Oncocyte has established partnerships with leading healthcare organizations, such as the Dana-Farber Cancer Institute and MD Anderson Cancer Center. These partnerships help to validate the company's tests and increase their adoption by clinicians.

Sales

Customer Segments

Oncocyte Corporation primarily targets the following customer segments:

1. Healthcare Providers

Physicians and other healthcare professionals who use Oncocyte's products for:
- Diagnostic testing
- Treatment selection
- Monitoring patient outcomes